Sign in or create an account to add this stock to your watchlist.
About ChromaDex (NASDAQ:CDXC)
ChromaDex Corporation operates as a nutraceutical company. The company offers research and quality control products and services to dietary supplements, food, beverages, cosmetic, and pharmaceutical industries; Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide(NAD) level used for healthy aging; Pterostilbene (pTeroPure), a polyphenol and antioxidant used in health related fields; and Immulina, a spirulina extract and compound, which is used for improving human immune function, as well as developing Pterostilbene and caffeine co-crystal ingredients, and anthocyanins ingredients. It also provides reference standards, materials, and kits to conduct quality control of raw materials and consumer products; and fine chemicals and phytochemicals for research and new product development applications. In addition, the company offers a range of consulting services, including regulatory support, product development, risk management, and litigation support. Further, it assists customers in creating processes for manufacturing natural products using green chemistry, as well as developing phytochemical libraries. The company markets and sells its products directly in the United States and Canada; and through international distributors. ChromaDex Corporation is based in Irvine, California.
Industry, Sector and Symbol
Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CDXC
CUSIPN/A
Phone949-419-0288
Debt
Debt-to-Equity Ratio0.01
Current Ratio5.22
Quick Ratio4.71
Price-To-Earnings
Trailing P/E Ratio-11.09
Forward P/E Ratio-11.41
P/E GrowthN/A
Sales & Book Value
Annual Sales$21.20 million
Price / Sales10.04
Cash FlowN/A
Price / CashN/A
Book Value$0.85 per share
Price / Book4.56
Profitability
EPS (Most Recent Fiscal Year)($0.35)
Net Income$-11,370,000.00
Net Margins-70.19%
Return on Equity-56.28%
Return on Assets-46.19%
Miscellaneous
Employees74
Outstanding Shares54,870,000
ChromaDex (NASDAQ:CDXC) Frequently Asked Questions
What is ChromaDex's stock symbol?
ChromaDex trades on the NASDAQ under the ticker symbol "CDXC."
How were ChromaDex's earnings last quarter?
ChromaDex (NASDAQ:CDXC) announced its earnings results on Thursday, May, 10th. The company reported ($0.15) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.06) by $0.09. The firm had revenue of $6.57 million for the quarter, compared to the consensus estimate of $6.50 million. ChromaDex had a negative net margin of 70.19% and a negative return on equity of 56.28%. View ChromaDex's Earnings History.
When is ChromaDex's next earnings date?
What price target have analysts set for CDXC?
2 brokerages have issued 1-year target prices for ChromaDex's shares. Their forecasts range from $7.00 to $8.00. On average, they expect ChromaDex's share price to reach $7.50 in the next year. View Analyst Ratings for ChromaDex.
What are Wall Street analysts saying about ChromaDex stock?
Here are some recent quotes from research analysts about ChromaDex stock:
- 1. According to Zacks Investment Research, "ChromaDex Corporation and its subsidiaries supply phytochemical reference standards and reference materials, related contract services, and products for the dietary supplement, nutraceutical, food and beverage, functional food, pharmaceutical and cosmetic markets. ChromaDex's core business strategy is to use the intellectual property harnessed by its expertise in the area of natural products and in the creation of reference materials to the industry as the basis for providing new and alternative, green, mass marketable products to its customers. The Company's main priority is to create industry-accepted information, and to provide products and services to every layer of the functional food, pharmaceutical, personal care and dietary supplement markets. The company markets and sells its products in the United States and Canada. It offers its products through distributors in Europe, South America, Korea, India, Japan, Australia, New Zealand, China, Indonesia, Malaysia, Singapore, Thailand, and Mexico. " (4/17/2018)
- 2. HC Wainwright analysts commented, "We note that the company’s revenues came in at $5.3M vs. our original forecast of $8M, while a net loss of $2.7M or $0.07 per share was also recorded vs. our projection for a positive EPS of $0.04. While R&D spending in the quarter was roughly in-line with our estimate at $728K vs. $700K, we note that COGS were slightly worse than our estimate, coming in at 57% vs. our projection of 49%. Given what we see as the current status of ChromaDex’s ingredients business, we have revised our 2017 revenue number to $24.3M, while we now project a net loss per share for 2017 of $0.14 vs. our prior forecast for EPS of $0.16 for the year." (8/11/2017)
Who are some of ChromaDex's key competitors?
Some companies that are related to ChromaDex include Foamix Pharmaceuticals (FOMX), MediWound (MDWD), Natural Alternatives International (NAII), Mannatech (MTEX), Pharmacyte Biotech (PMCB), China Jo-Jo Drugstores (CJJD), GLG Life Tech (GLGLF), Cyanotech (CYAN), ImmuDyne (IMMD), FitLife Brands (FTLF), Nutra Pharma (NPHC), Tauriga Sciences (TAUG), True Drinks (TRUU), Entia Biosciences (ERGO) and Rock Creek Pharmaceutical (RCPIQ).
Who are ChromaDex's key executives?
ChromaDex's management team includes the folowing people:
- Mr. Frank Louis Jaksch Jr., Co-Founder, Chief Exec. Officer and Director (Age 50)
- Mr. Robert N. Fried, Pres, Chief Strategy Officer, COO and Director (Age 58)
- Mr. Thomas C. Varvaro, Consultant (Age 48)
- Mr. Troy Allen Rhonemus, Exec. VP (Age 45)
- Mr. Kevin M. Farr, Chief Financial Officer (Age 60)
Has ChromaDex been receiving favorable news coverage?
News headlines about CDXC stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ChromaDex earned a coverage optimism score of 0.11 on Accern's scale. They also assigned media headlines about the company an impact score of 44.83 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future.
Who are ChromaDex's major shareholders?
ChromaDex's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Millennium Management LLC (0.92%), UBS Group AG (0.22%), Oppenheimer & Co. Inc. (0.17%), Granite Investment Partners LLC (0.16%), Tibra Equities Europe Ltd (0.14%) and Barclays PLC (0.12%). Company insiders that own ChromaDex stock include Frank L Jaksch Jr, Mark J Friedman, River Ventures Ltd Champion, Robert N Fried, Step Holdings Ltd Pioneer, Stephen R Allen and Troy Allen Rhonemus. View Institutional Ownership Trends for ChromaDex.
Which institutional investors are selling ChromaDex stock?
Which institutional investors are buying ChromaDex stock?
CDXC stock was acquired by a variety of institutional investors in the last quarter, including Tibra Equities Europe Ltd, Citadel Advisors LLC, UBS Group AG, Oppenheimer & Co. Inc., Element Capital Management LLC and Northern Trust Corp. Company insiders that have bought ChromaDex stock in the last two years include Frank L Jaksch Jr, Mark J Friedman, River Ventures Ltd Champion, Robert N Fried, Step Holdings Ltd Pioneer, Stephen R Allen and Troy Allen Rhonemus. View Insider Buying and Selling for ChromaDex.
How do I buy shares of ChromaDex?
Shares of CDXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ChromaDex's stock price today?
One share of CDXC stock can currently be purchased for approximately $3.88.
How big of a company is ChromaDex?
ChromaDex has a market capitalization of $212.88 million and generates $21.20 million in revenue each year. The company earns $-11,370,000.00 in net income (profit) each year or ($0.35) on an earnings per share basis. ChromaDex employs 74 workers across the globe.
How can I contact ChromaDex?
ChromaDex's mailing address is 10005 Muirlands Blvd. Suite G, IRVINE CA, 92618. The company can be reached via phone at 949-419-0288 or via email at [email protected]
MarketBeat Community Rating for ChromaDex (CDXC)
MarketBeat's community ratings are surveys of what our community members think about ChromaDex and other stocks. Vote "Outperform" if you believe CDXC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDXC will underperform the S&P 500 over the long term. You may vote once every thirty days.
ChromaDex (NASDAQ:CDXC) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
2 Wall Street analysts have issued ratings and price targets for ChromaDex in the last 12 months. Their average twelve-month price target is $7.50, suggesting that the stock has a possible upside of 93.30%. The high price target for CDXC is $8.00 and the low price target for CDXC is $7.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $7.50 | $7.50 | $7.50 | $6.3333 |
| Price Target Upside: | 93.30% upside | 78.57% upside | 44.79% upside | 47.29% upside |
ChromaDex (NASDAQ:CDXC) Consensus Price Target History
ChromaDex (NASDAQ:CDXC) Analyst Ratings History
Show:
(Data available from 5/20/2016 forward)
ChromaDex (NASDAQ:CDXC) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
ChromaDex (NASDAQ CDXC) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 11.59%
Institutional Ownership Percentage: 9.82%
ChromaDex (NASDAQ CDXC) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/17/2018 | Mark J Friedman | General Counsel | Buy | 3,000 | $3.60 | $10,800.00 | |  |
| 5/16/2018 | Frank L Jaksch Jr | CEO | Buy | 9,800 | $3.59 | $35,182.00 | | |
| 5/15/2018 | Robert N Fried | COO | Buy | 10,000 | $3.63 | $36,300.00 | | |
| 3/29/2018 | Frank L Jaksch Jr | CEO | Sell | 474 | $4.60 | $2,180.40 | | |
| 3/27/2018 | Frank L Jaksch Jr | CEO | Sell | 24,578 | $4.60 | $113,058.80 | | |
| 1/11/2018 | Frank L Jaksch Jr | CEO | Sell | 28,379 | $6.52 | $185,031.08 | | |
| 12/21/2017 | Frank L Jaksch Jr | CEO | Sell | 58,400 | $6.19 | $361,496.00 | | |
| 11/17/2017 | River Ventures Ltd Champion | Major Shareholder | Buy | 731,707 | $4.10 | $2,999,998.70 | | |
| 8/25/2017 | Stephen R Allen | Director | Buy | 2,000 | $3.31 | $6,620.00 | 7,000 | |
| 8/18/2017 | Step Holdings Ltd Pioneer | Major Shareholder | Buy | 786,167 | $2.60 | $2,044,034.20 | | |
| 8/15/2017 | Robert N Fried | Insider | Buy | 10,000 | $3.15 | $31,500.00 | 583,241 | |
| 5/24/2017 | Step Holdings Ltd Pioneer | Major Shareholder | Buy | 2,521,526 | $2.60 | $6,555,967.60 | | |
| 5/19/2017 | Stephen R Allen | Director | Buy | 3,000 | $3.20 | $9,600.00 | 5,000 | |
| 3/20/2017 | Stephen R Allen | Director | Buy | 2,000 | $2.81 | $5,620.00 | 2,000 | |
| 12/12/2016 | Frank L Jaksch Jr | CEO | Buy | 2,000 | $2.42 | $4,840.00 | 201,557 | |
| 9/1/2016 | Frank L Jaksch Jr | CEO | Buy | 1,500 | $3.32 | $4,980.00 | 199,557 | |
| 9/1/2016 | Robert N Fried | Director | Buy | 15,000 | $3.39 | $50,850.00 | 66,979 | |
| 6/20/2016 | Troy Allen Rhonemus | COO | Buy | 7,800 | $3.47 | $27,066.00 | | |
(Data available from 1/1/2013 forward)
ChromaDex (NASDAQ CDXC) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | ChromaDex (CDXC) General Counsel Acquires $10,800.00 in Stock
www.americanbankingnews.com - May 17 at 8:55 PM |
| ChromaDex (CDXC) CEO Purchases $35,182.00 in Stock
www.americanbankingnews.com - May 16 at 8:52 PM |
| ChromaDex (CDXC) COO Robert N. Fried Purchases 10,000 Shares
www.americanbankingnews.com - May 16 at 1:25 PM |
| HC Wainwright Analysts Give ChromaDex (CDXC) a $8.00 Price Target
www.americanbankingnews.com - May 14 at 12:42 PM |
 | ChromaDex Appoints Nobel Laureate, Professor Sir John Walker, to the Scientific Advisory Board
feeds.benzinga.com - May 14 at 6:55 AM |
 | ChromaDex's (CDXC) CEO Frank Jaksch on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 11 at 10:19 AM |
 | Edited Transcript of CDXC earnings conference call or presentation 10-May-18 8:30pm GMT
finance.yahoo.com - May 11 at 10:19 AM |
| ChromaDex (CDXC) Releases Quarterly Earnings Results, Misses Expectations By $0.09 EPS
www.americanbankingnews.com - May 10 at 8:29 PM |
| ChromaDex Corporation Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 10 at 4:40 PM |
| ChromaDex Corporation’s (NASDAQ:CDXC) Path To Profitability
finance.yahoo.com - May 9 at 4:34 PM |
| ChromaDex (CDXC) Given a $8.00 Price Target at HC Wainwright
www.americanbankingnews.com - May 7 at 2:56 PM |
| Head-To-Head Review: ChromaDex (CDXC) and Foamix Pharmaceuticals (FOMX)
www.americanbankingnews.com - May 4 at 11:07 PM |
| ValuEngine Upgrades ChromaDex (CDXC) to "Hold"
www.americanbankingnews.com - May 3 at 10:18 PM |
| ChromaDex Sets First Quarter 2018 Financial Results on Thursday, May 10, 2018
finance.yahoo.com - May 3 at 9:17 AM |
 | ChromaDex (CDXC): Moving Average Crossover Alert
www.zacks.com - May 2 at 9:22 AM |
| ChromaDex (CDXC) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - May 2 at 3:14 AM |
 | ChromaDex (CDXC) Says it Remains Confident Amidst Inter Partes Review Procedural Changes
www.streetinsider.com - May 1 at 4:27 PM |
| ChromaDex Remains Confident Amidst Inter Partes Review (IPR) Procedural Changes
finance.yahoo.com - May 1 at 9:25 AM |
| USANA Health Sciences (USNA) & ChromaDex (CDXC) Head to Head Review
www.americanbankingnews.com - April 30 at 3:20 AM |
| Critical Analysis: ChromaDex (CDXC) and Foamix Pharmaceuticals (FOMX)
www.americanbankingnews.com - April 26 at 10:06 AM |
| Reviewing True Drinks (TRUU) & ChromaDex (CDXC)
www.americanbankingnews.com - April 26 at 1:24 AM |
 | BRIEF-Chromadex Corp Appoints Rob Fried as Chief Executive Officer
www.reuters.com - April 24 at 9:24 AM |
 | ChromaDex Appoints Frank Jaksch As Executive Chairman, Rob Fried as Chief Executive Officer and Kurt Gustafson ...
globenewswire.com - April 23 at 4:28 PM |
| ChromaDex Appoints Frank Jaksch As Executive Chairman, Rob Fried as Chief Executive Officer and Kurt Gustafson as Lead Director
finance.yahoo.com - April 23 at 4:28 PM |
| ChromaDex (CDXC) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - April 20 at 7:28 PM |
| ChromaDex (CDXC) versus USANA Health Sciences (USNA) Head-To-Head Contrast
www.americanbankingnews.com - April 20 at 1:26 AM |
 | Pre-Market Technical Scan on Chemicals Equities -- Celanese, ChromaDex, Rayonier Advanced Materials, and ...
www.prnewswire.com - April 18 at 9:26 AM |
| ChromaDex (CDXC) Downgraded to Strong Sell at Zacks Investment Research
www.americanbankingnews.com - April 17 at 8:43 PM |
| Critical Survey: Stada Arzneimittel (STDAF) and ChromaDex (CDXC)
www.americanbankingnews.com - April 14 at 5:28 AM |
| Analyzing Stada Arzneimittel (STDAF) & ChromaDex (CDXC)
www.americanbankingnews.com - April 13 at 3:39 PM |
| TRU NIAGEN® to be featured at the American Academy of Anti-Aging Medicine Spring Congress
feeds.benzinga.com - April 5 at 7:55 AM |
| Insider Selling: Chromadex Corp (CDXC) CEO Sells 24,578 Shares of Stock
www.americanbankingnews.com - March 29 at 10:46 PM |
| ChromaDex (CDXC) Announces Published Results from Human Clinical Study of NIAGEN
www.streetinsider.com - March 29 at 9:49 AM |
| New Published Clinical Trial Confirms NIAGEN® Supplementation Raised Nicotinamide Adenine Dinucleotide (NAD) Levels and Potentially Improves Blood Pressure and Cardiovascular Health
finance.yahoo.com - March 29 at 9:49 AM |
| Chromadex (CDXC) Downgraded by BidaskClub to "Hold"
www.americanbankingnews.com - March 28 at 12:34 AM |
| Head-To-Head Comparison: Anthera Pharmaceuticals (ANTH) & Chromadex (CDXC)
www.americanbankingnews.com - March 20 at 3:34 AM |
| Edited Transcript of CDXC earnings conference call or presentation 8-Mar-18 9:30pm GMT
finance.yahoo.com - March 18 at 9:21 AM |
| Chromadex (CDXC) Downgraded by ValuEngine to "Sell"
www.americanbankingnews.com - March 11 at 3:19 PM |
| Chromadex (CDXC) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - March 9 at 7:30 PM |
| ChromaDex's (CDXC) CEO Frank Jaksch on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 9 at 9:58 AM |
| Chromadex (CDXC) Releases Earnings Results, Misses Expectations By $0.14 EPS
www.americanbankingnews.com - March 9 at 12:38 AM |
| ChromaDex reports 4Q loss
finance.yahoo.com - March 8 at 5:24 PM |
| ChromaDex Corporation Reports 2017 Financial Results
finance.yahoo.com - March 8 at 5:24 PM |
| ChromaDex to Present at the 30th Annual ROTH Conference on March 12, 2018
finance.yahoo.com - March 6 at 9:16 AM |
| Chromadex (CDXC) to Release Quarterly Earnings on Thursday
www.americanbankingnews.com - March 5 at 6:10 PM |
| Chromadex (CDXC) PT Set at $8.00 by HC Wainwright
www.americanbankingnews.com - March 5 at 2:58 PM |
| Tieton Capital Management LLC Trims Holdings in Chromadex Corp (CDXC)
www.americanbankingnews.com - February 27 at 4:14 PM |
| Brokerages Anticipate Chromadex Corp (CDXC) to Announce -$0.01 Earnings Per Share
www.americanbankingnews.com - February 26 at 10:48 AM |
| Two Additional Collaborative Human Studies on NIAGEN® with the University of Cambridge and the University of Washington Now Registered on Clinical-trials.gov.
finance.yahoo.com - February 20 at 9:04 AM |
| BRIEF-Chromadex Chairman Stephen Allen Will Retire From The Board
www.reuters.com - February 17 at 8:58 AM |
ChromaDex (NASDAQ:CDXC) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
ChromaDex (NASDAQ CDXC) Stock Chart for Sunday, May, 20, 2018
Loading chart…
